Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Dermatologic Therapy - 2021 - Moravvej - Androgenetic Alopecia and COVID 19 A Review of The Hypothetical Role of Androgens Es
Dermatologic Therapy - 2021 - Moravvej - Androgenetic Alopecia and COVID 19 A Review of The Hypothetical Role of Androgens Es
RE VI E W AR T I C L E
KE Y W O R D S
alopecia androgenética, enfermedad por coronavirus 2019, COVID-19, infección por SARS-
CoV-2, tratamiento
2 | MATERIALES Y MÉTODOS
3 | RESULTADOS Y DISCUSIÓN
4 | CONCLUSIÓN
CONFLICTO DE INTERESES
Los autores declaran no tener ningún conflicto de intereses.
2020;33:e14443.
REFERENCIAS
1. Cuadro de mando de la OMS sobre la enfermedad por coronavirus
(COVID-19). https://covid19. who.int
2. Borges do Nascimento IJ, Cacic N, Abdulazeem HM, et al. Novel
coro- navirus infection (COVID-19) in humans: a scoping review and
meta- analysis. J Clin Med. 2020;9(4):941.
3. Foresta C, Rocca M, Di Nisio A. Gender susceptibility to COVID-19:
a review of the putative role of sex hormones and X chromosome. J
Endocrinol Invest. 2020;44:1-6.
4. Cattrini C, Bersanelli M, Latocca MM, Conte B, Vallome G,
Boccardo F. Sex hormones and hormone therapy during covid-19
pandemic: implications for patients with cancer. Cancer. 2020;12(8):
2325.
5. Barat T, Abdollahimajd F, Dadkhahfar S, Moravvej H. Evaluation of
the efficacy and safety of cow placenta extract lotion compared to
minoxidil 2% in the treatment of female pattern androgenetic alope-
cia. Int J Womens Dermatol. 2020;6:318-321.
6. Wambier CG, Vaño-Galv'an S, McCoy J, et al. Alopecia androgenética
presente en la mayoría de los pacientes hospitalizados por COVID-
19-el
"Signo de Gabrin". J Am Acad Dermatol. 2020;83:680-682.
7. Mirmirani P. Age-related hair changes in men: mechanisms and
man- agement of alopecia and grayying. Maturitas. 2015;80(1):58-
62.
8. Goren A, Vaño-Galv'an S, Wambier CG, et al. A preliminary observa-
Pérdida de pelo de patrón masculino entre los pacientes
hospitalizados por COVID-19 en España: una posible pista sobre el
papel de los andrógenos en la gravedad de COVID-19. J Cosmet
Dermatol. 2020;19:1545-1547.
9. Nanes BA. Alopecia androgenética en COVID-19: ¿comparada con
qué?
J Am Acad Dermatol. 2020;83(6):e451.
10. Lee J, Yousaf A, Fang W, Kolodney MS. La calvicie masculina es
un factor de riesgo importante de COVID-19 grave. J Am Acad
Dermatol. 2020;83(5):e353- e354.
11. Thatiparthi A, Liu J, Martin A, Wu JJ. Letter to the editor: a response
to 'male balding is a major risk factor for severe COVID-19'. J Am
Acad Dermatol. 2021;84(2):e87-e88.
12. Yousaf A, Kolodney M. Reply to letter to the editor: "a response to
'male balding is a major risk factor for severe COVID-19'". J Am
Acad Dermatol. 2020;84(2):e89.
13. Wambier CG, Vaño-Galv'an S, McCoy J, Pai S, Dhurat R, Goren A.
Androgenetic alopecia in COVID-19: compared to age-matched epi-
demiologic studies and hospital outcomes with or without the Gabrin
sign. J Am Acad Dermatol. 2020;83(6):e453-e454.
14. Müller Ramos P, Ianhez M, Amante Miot H. La alopecia y las canas
se asocian con la gravedad de COVID-19. Exp Dermatol.
2020;29(12): 1250-1252.
15. Wambier CG, Goren A. Severe acute respiratory syndrome
coronavi- rus 2 (SARS-CoV-2) infection is likely to be androgen
mediated. J Am Acad Dermatol. 2020;83(1):308-309.
16. Goren A, Wambier CG, Herrera S, et al. Anti-androgens may protect
against severe COVID-19 outcomes: results from a prospective
cohort study of 77 hospitalized men. J Eur Acad Dermatol Venereol.
2021;35(1):e13-e15.
17. McCoy J, Wambier CG, Herrera S, et al. Androgen receptor genetic
variant predicts COVID-19 disease severity: a prospective longitudi-
nal study of hospitalized COVID-19 male patients. J Eur Acad
Dermatol Venereol. 2021;35(1):e15-e17.
18. Wambier CG, Goren A, Vaño-Galv'an S, et al. Sensibilidad a los
andrógenos
gateway to COVID-19 disease severity. Drug Dev Res. 2020;81:
771-776.
19. Sabharwal N, Sharifi N. HSD3B1 genotypes conferring adrenal-
restrictive and adrenal-permissive phenotypes in prostate cancer
and beyond. Endocrinology. 2019;160(9):2180-2188.
20. Pourani MR, Abdollahimajd F. CD147 as a novel receptor in the
path- ogenesis of SARS-CoV-2: is there any correlation with risk of
COVID- 19 in dermatological diseases? Dermatol Ther.
21. Xu Z, Wang Y, Xiao ZG, et al. Nuclear receptor ERRα and
transcrip- tion factor ERG form a reciprocal loop in the regulation
of TMPRSS2: ERG fusion gene in prostate cancer. Oncogene.
2018;37(48):6259- 6274.
22. Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and
TMPRSS2 variants and expression as candidates to sex and
country differences in COVID-19 severity in Italy. Aging (Albany
NY). 2020;12(11):10087- 10098.
23. Pourani MR, Nekooghadam SM, Youssefian L, Vahidnezhad H,
Abdollahimajd F. CD147 inhibitors as a treatment for melanoma:
promising agents against SARS-CoV-2 infection. Dermatol Ther.
2020; 33:e14449.
24. Bhowmick NA, Oft J, Dorff T, et al. COVID-19 y la terapia dirigida
a andrógenos para pacientes con cáncer de próstata. Endocr Relat
Cancer. 2020;27(9): R281-R292.
25. Baratchian M, McManus JM, Berk M, et al. Sex, androgens and
regu- lation of pulmonary AR, TMPRSS2 and ACE2. bioRxiv;
2020.
26. Ziegler CG, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor
ACE2 is an interferon-stimulated gene in human airway epithelial
cells and is detected in specific cell subsets across tissues. Cell.
2020;181: 1016-1035.e19.
27. Strope JD, Chau CH, Figg WD, eds. ¿Están relacionados los
resultados discordantes por sexo en COVID-19 con las hormonas
sexuales? Sem Oncol. 2020;47:335-340.
28. Hoffmann M, Kleine-Weber H, Schroeder S, et al. La entrada
celular de SARS-CoV-2 depende de ACE2 y TMPRSS2 y es
bloqueada por un inhibidor de proteasa clínicamente probado.
Cell. 2020;181:271-280.e8.
29. Al-Lami RA, Urban RJ, Volpi E, Algburi AM, Baillargeon J. Sex
hor- mones and novel corona virus infectious disease (COVID-
19): Mayo Clinic Proceedings; 2020; Elsevier.
30. Zeng F, Dai C, Cai P, et al. A comparison study of SARS-CoV-2
IgG antibody between male and female COVID-19 patients: a
possible reason underlying different outcome between sex. J Med
Virol. 2020; 92(10):2050-2054.
31. Kalra S, Bhattacharya S, Kalhan A. Testosterone in COVID-19-
foe, friend or fatal victim? Eur Endocrinol. 2020;16(2):88.
32. Pozzilli P, Lenzi A. Comentario: la testosterona, una hormona
clave en el contexto de la pandemia de COVID-19. Metabolism.
2020;108:154252.
33. McCoy J, Cadegiani FA, Wambier CG, et al. 5-alpha-reductase
inhibi- tors are associated with reduced frequency of COVID-19
symptoms in males with Androgenetic alopecia. J Eur Acad
Dermatol Venereol. 2020;35(4):e243-e246.
34. Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation
therapies for prostate cancer and risk of infection by SARS-CoV-
2: a population-based study (n= 4532). Ann Oncol. 2020;31:1040-
1045.
35. Patel VG, Zhong X, Liaw B, et al. ¿Protege la terapia de privación
androgénica contra las complicaciones graves del COVID-19?
Ann Oncol. 2020;31(10):1419-1420.
36. Caffo O, Zagonel V, Baldessari C, et al. On the relationship
between androgen-deprivation therapy for prostate cancer and
risk of infec- tion by SARS-CoV-2. Ann Oncolon. Ann Oncol.
2020;31(10):1415-1416.
37. Koskinen M, Carpen O, Honkanen V, et al. Androgen deprivation
and SARS-CoV-2 in men with prostate cancer. Ann Oncol.
2020;31:1417- 1418.
38. Ory J, Lima TFN, Towe M, et al. Understanding the complex
relation- ship between androgens and SARS-CoV2. Urology.
2020;144:1-3.
39. Leach DA, Isac A-M, Bevan CL, Brooke GN. TMPRSS2, required
for SARS-CoV-2 entry, is downregulated in lung cells by
enzalutamide, a prostate cancer therapeutic; 2020.
40. Bennani N, Bennani-Baiti I. Androgen deprivation therapy may
consti- tute a more effective COVID-19 prophylactic than
therapeutic strat- egy. Ann Oncol. 2020;31(11):1585-1586.
41. Ehdaie B, Atoria CL, Gupta A, et al. Androgen deprivation and
throm- boembolic events in men with prostate cancer. Cancer.
2012;118(13): 3397-3406.
aplicable.
15298019, 2021, 4, Descargado de https://onlinelibrary.wiley.com/doi/10.1111/dth.15004 por Readcube (Labtiva Inc.), Wiley Online Library el [05/07/2023]. Consulte los Términos y Condiciones (https://onlinelibrary.wiley.com/terms-and-conditions) en Wiley Online Library para conocer las normas de uso; los artículos OA se rigen por la Licencia Creative Commons
MORAVVEJ ET AL. 7 de7
42. Rastrelli G, Di Stasi V, Inglese F, et al. Low testosterone levels 51. Kroumpouzos G. Effects of 5-alpha reductase inhibitors on lung
predict clinical adverse outcomes in SARS-CoV-2 pneumonia function: a reason for discontinuation during COVID-19 pandemic?
patients. Andrology. 2021;9(1):88-98. Dermatol Ther. 2020;33:e13535.
43. Salciccia S, Del Giudice F, Gentile V, et al. Interplay between male 52. Lee JH, Kim YC, Cho SH, et al. The effect of sex hormone on
tes- tosterone levels and the risk for subsequent invasive respiratory COVID- 19: analysis of laboratory-confirmed 5061 patients in South
assistance among COVID-19 patients at hospital admission. Endo- Korea. Menopause. 2020;27(12):1376-1381.
crine. 2020;70(2):206-210. 53. Ianhez M, Ramos PM, Goren A, Miot HA. Sensibilidad androgénica
44. Ma L, Xie W, Li D, et al. Effect of SARS-CoV-2 infection upon male en COVID-19 y antiandrógenos: aún se necesitan datos
gonadal function: a single center-based study. MedRxiv. 2020. prospectivos. Dermatol Ther. 2020;33:e14166.
https://doi.org/10.1101/2020.03.21.20037267. 54. Cadegiani FA, Goren A, Wambier CG, McCoy J. Azitromicina con
45. Rambhatla A, Bronkema CJ, Corsi N, et al. COVID-19 infection in nitazoxanida, hidroxicloroquina o ivermectina, con o sin dutasterida,
men on testosterone replacement therapy. J Sex Med. 2021;18(1): para la COVID-19 en fase inicial: un estudio observacional
215-218. prospectivo abierto en varones con COVID-19 de leve a moderada
46. Cadegiani F, Lim R, Goren A, et al. Síntomas clínicos de mujeres (The Pre-AndroCoV Male Trial); 2020.
hiperandrogénicas diagnosticadas con COVID-19. J Eur Acad
Dermatol Venereol. 2021;35(2):e101-e104.
47. Cadegiani FA. Repurposing existing drugs for COVID-19: an INFORMACIÓN COMPLEMENTARIA
endocri- nology perspective. BMC Endocr Disord. 2020;20(1):1-19. Encontrará más información de apoyo en la sección Información de
48. Liaudet L, Szabo C. Blocking mineralocorticoid receptor with spi-
apoyo al final de este artículo.
ronolactone may have a wide range of therapeutic actions in severe
COVID-19 disease. Crit Care. 2020;24(1):1-2.
49. Lazzeri M, Azzolini E, Buffi NM, et al. Impact of anti-androgenic
therapies on COVID-19: an observational study in male population Cómo citar este artículo: Moravvej H, Pourani MR, Baghani M,
from a COVID-19 regional centre of Lombardy (Italy). medrxiv; Abdollahimajd F. Alopecia androgenética y COVID-19: A review
2020. of the hypothetical role of androgens. Dermatologic Therapy.
50. Adamowicz J, Juszczak K, Drewa T. ¿Pueden los pacientes que
2021;34(4):e15004. https://doi.org/10.1111/dth.
reciben inhibidores de la 5-alfa reductasa presentar un mayor riesgo
de complicaciones COVID-19? Med Hypotheses. 2020;140:109751. 15004